NNVC - NanoViricides, Inc.
7.25 -0.09 (-1.23%)
Pre-Market: 7:33AM EST
| Previous Close | 7.69 |
| Open | 7.11 |
| Bid | 7.16 x 1400 |
| Ask | 7.25 x 1300 |
| Day's Range | 7.10 - 7.61 |
| 52 Week Range | 1.27 - 19.20 |
| Volume | 1,016,789 |
| Avg. Volume | 3,337,088 |
| Market Cap | 49.391M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.12 |
| Earnings Date | Feb 17, 2020 - Feb 20, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.60 |
- ACCESSWIRE
Dr. Mak Jawadekar Joins the Board of Directors of NanoViricides, Inc.
SHELTON, CT / ACCESSWIRE / February 12, 2020 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, reports that Dr. Makarand "Mak" Jawadekar, a veteran Pharma industry expert professional, has been duly appointed as an Independent Director to its Board of Directors. Dr. Mak Jawadekar has been serving as a strategic advisor to pharmaceutical and biotechnology companies through his independent consultancy since 2010.
- ACCESSWIRE
Nanoviricides President Dr. Diwan Was Interviewed by The Varney Show on Fox Business News
SHELTON, CT / ACCESSWIRE / February 10, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that Dr. Anil Diwan, the Company's President and Executive Chairman of the Board, was interviewed on the Stuart Varney show on Fox Business News (FBN), on January 28, 2020. The Company has licensed a copy of the video excerpt from FBN and it is available on the Company's website (www.nanoviricides.com), home page, under the heading "Dr. Anil Diwan on Fox Business - 01/28/2020".
- Zacks
Can Biotech ETFs Continue to Soar in 2020?
We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.
- ACCESSWIRE
Nanoviricides President Dr. Diwan Was Interviewed By The Kennedy Show On Fox Business News
SHELTON, CT / ACCESSWIRE / February 4, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that Dr. Anil Diwan, the Company's President and Executive Chairman of the Board, was interviewed on the Kennedy show on Fox Business News (FBN), on January 23, 2020. In discussing the recent Wuhan coronavirus (2019-nCoV) outbreak, Ms. Kennedy asked Dr. Diwan how such outbreaks can be treated, and how the nanoviricides technology can be harnessed for that effect.
- MarketWatch
Coronavirus update: 361 have died, there are now 11 cases in the U.S. and the case count has doubled SARS
U.S. health officials expanded the number of airports that U.S. citizens returning from China’s Hubei Province will be funneled through as part of the government’s efforts to stem the spread of the coronavirus.
- Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Mon., Feb. 3, 2020: SYY, PCG, NNVC, UBER, TSLA
Benzinga Pro's Stocks To Watch For Monday Sysco (SYY) - Reported mixed Q2 results: beat on the bottom line but missed on the sales figure. Shares were up 0.5% ahead of the opening bell. PG&E (PCG) - ...
- MarketWatch
Coronavirus update: WHO says prepare for local coronavirus outbreaks in other countries
President Donald Trump’s coronavirus task force on Friday announced a series of actions aimed at stemming the spread of the coronavirus outbreaks, including declaring a public-health emergency in the U.S.
- Benzinga
The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
- ACCESSWIRE
NanoViricides Confirms It Has Been Working On A Treatment For The Novel Wuhan Coronavirus
SHELTON, CT / ACCESSWIRE / January 30, 2020 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is confirming public disclosures in articles by various industry journals and other articles, that it is working on developing a treatment for the novel coronavirus 2019-nCoV, or the Wuhan coronavirus. At this time, the Company does not have a collaboration with any of these agencies, and we have not been contacted by any of these entities or asked to develop a treatment for this virus. In fact it has been shown to use the same cell surface receptor as SARS-CoV, namely ACE2.
- GuruFocus.com
These 4 Biotech Stocks Are the Silver Lining on the Wuhan Coronavirus
Anti-viral pharma companies catering to respiratory disorders performed solidly during the SARS outbreak, and history might repeat itself with this new virus Continue reading...
- MarketWatch
Coronavirus update: Vaccine stocks retreat and airport screening expands to 20 U.S. airports
A nearly weeklong rally for vaccine and diagnostics developers looking to capitalize on the coronavirus outbreak ended on Tuesday.
- Yahoo Finance
Stock market news live: Stocks close lower as coronavirus death toll rises
Headlines moving the stock market in real time.
- MarketWatch
CDC officials say coronavirus is similar to SARS, no new U.S. cases reported
At least 110 people in 26 states have been identified as persons under investigation for coronavirus, Centers for Disease Control and Prevention officials said Monday.
- Yahoo Finance
Analyst: China's coronavirus victims 'probably 10 times' higher than reported
As the number of patients stricken by China’s coronavirus continues to mount, at least one analyst believes the country’s reported casualty count might be far higher than Beijing has publicly admitted.
- MarketWatch
Vaccine, diagnostics stocks rise again on spreading coronavirus
Shares of a handful of vaccine makers, diagnostics companies and manufacturers of medical supplies, like masks, rallied again in premarket trading on Monday over growing public concern about the new coronavirus. This includes Co-Diagnostics Inc. , up 42%; NanoViricides Inc. , up 29%; Allied Healthcare Products Inc. , up 22%; Inovio Pharmaceuticals Inc. , up 24%; and Novavax Inc. , up 13%. The Centers for Disease Control and Prevention said Sunday that there are now five confirmed cases in the U.S., all of whom had traveled to Wuhan, the city in China where the virus was first identified. Chinese health officials have said that more than 2,700 people have been sickened and at least 80 people died, according to The Wall Street Journal. Market concerns have sent global stocks and U.S. futures tumbling on Monday. The S&P 500 and the Dow Jones Industrial Average are both 1% over the last week.
- ACCESSWIRE
NanoViricides Closes on $8.625 Million Underwritten Public Offering of Common Stock
SHELTON, CONNECTICUT / ACCESSWIRE / January 24, 2020 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has completed an underwritten public offering (the "Offering") with gross proceeds of $8.625 million before deducting underwriting discounts and other estimated offering expenses. The Offering included 2.5 million shares of the Company's common stock, and 375,000 additional shares from the exercise of the underwriter's option to purchase to cover over-allotments at the public offering price of $3.00 per share. The net proceeds to the Company after underwriter's commission and agreed upon customary fees and expenses were approximately $7.78 million, before deducting the Company's legal and accounting expenses related to the Offering.
- ETF Trends
Biotech ETFs Are Not Riding the Wave from Coronavirus Panic
Despite concerns of a spreading coronavirus out of China, biotechnology stocks and sector-related ETFs are not enjoying the usual bump on hopes of developing new treatments to counter the contagion. Among the worst performing non-leveraged ETFs of Friday, the Virtus LifeSci Biotech Clinical Trials ETF (BBC) declined 3.4% and SPDR S&P Biotech ETF (XBI) decreased 3.2%. Meanwhile, the more broadly watched iShares Nasdaq Biotechnology ETF (IBB) fell 2.5%.
- Benzinga
13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak
Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter. Alpha Pro Tech, Ltd. (NYSE: APT) manufactures masks and protective apparel — goods already in high demand in China. Lakeland Industries, Inc. (NASDAQ: LAKE) also produces protective clothes for high-risk workers, such as the medical professionals and public health officials exposing themselves to patients.
- MarketWatch
UPDATE: Vaccine stocks rise sharply as coronavirus fears mounts
Shares of vaccine makers rose sharply again on Thursday, amid rising concerns about the outbreak of a new coronavirus in Wuhan, China that has led the authorities to quarantine the city of 11 million. Novavax Inx. , which developed a vaccine for MERS (Middle East respiratory syndrome) in 2013, gained 9% in early trade, while Moderna Inc. was up 2%. The company said it will work with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine to treat the new illness. Inovio Pharmaceuticals Inc. shares rose 9%, after that company said the CEPI has given it a grant of up to $9 million to develop a vaccine against the virus. NanoViricides , which rallied on the first reports of the news before falling back after it issued 2.5 million shares, soared 45%. The virus was first identified in December in Wuhan City, China. It has since sickened more than 599 people, including a U.S. resident who had traveled to Wuhan this month, according to the Centers for Disease Control and Prevention. China has reported 17 deaths. Health officials now believe the virus is spread human to human. The SPDR S&P Biotech ETF has gained 18% in the last 12 months, while the S&P 500 has gained 26%.
- Zacks
3 Biotech Stocks Likely to Gain as Coronavirus Spreads
Here we discuss three biotech stocks, which are likely to benefit in case there is an outbreak of coronavirus infection in China.
- Zacks
The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech
The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech
- MarketWatch
Vaccine makers tap into virus-driven rally to raise money
Some small vaccine developers that saw their stocks take off on Tuesday over growing concern about the new coronavirus are using the market interest to raise money.
- Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Wed., Jan. 22, 2020: NFLX, TSLA, NNVC, SKT, SPCE
Benzinga Pro's Stocks To Watch For Wednesday Netflix (NFLX) - Shares were up just 0.4% following a Q4 beat and mixed Q1 guidance. The company said it expects Q1 global streaming paid net subscriber additions ...
- Zacks
Coronavirus Infects Wall Street: Stocks to Gain & Lose
While travel-related stocks were hit hard on concerns over coronavirus, experimental vaccine companies rallied.
